Table III. Individual and Mean Results for Spirometry and Adenosine Challenge (n =15 patients who completed both placebo and omalizumab treatment periods).

	Placebo						Omalizumab
	FEV1 (Liters)			PC20			FEV1 (Liters)			PC20
Subject	Before	End	% Change	Before	End	Fold Change*	Before	End	% Change	Before	End	Fold Change*
Order = OMA/Placebo
1	1.85	1.96	6	146.4	19.93	0.1	1.90	1.72	-9	10.3	182.34	17.8
4	3.68	3.96	8	60.8	72.09	1.2	4.02	3.98	-1	39.8	30.46	0.8
9	2.08	2.65	27	17.1	20.36	1.2	2.47	2.43	-2	12.2	35.74	2.9
14††	2.21	2.42	10	16.6	15.89	1.0	2.01	1.99	-1	13.8	117.28	8.5
16	3.44	3.64	6	31.2	29.34	0.9	2.69	2.87	7	9.22	4.81	0.5
21	2.48	2.69	8	4.40	16.24	3.7	2.61	2.50	-4	9.67	4.93	0.5
36	4.42	4.31	-2	85.8	22.53	0.3	4.20	4.58	9	19.2	65.06	3.4
Order = Placebo/OMA
3	2.63	2.89	10	19.7	54.23	2.8	2.70	2.73	1	65.2	>200	3.1
6††	4.13	4.26	3	12.3	7.80	0.6	3.59	4.82	34	3.10	15.51	5.0
10††	2.55	2.81	10	10.9	5.23	0.5	2.39	3.22	35	2.45	5.93	2.4
13††	3.14	3.25	4	9.30	52.78	5.7	2.88	3.14	9	5.17	141.30	27.3
27††	2.81	2.60	-7	5.50	2.64	0.5	2.27	2.40	6	1.05	4.45	4.2
30	3.23	3.19	-1	40.8	158.09	3.9	3.23	3.35	4	27.8	>200	7.2
34	2.44	2.26	-7	15.4	2.91	0.2	2.54	2.47	-3	20.2	90.51	4.5
38††	1.80	2.02	12	13.9	14.81	1.1	1.96	2.16	10	17.6	11.86	0.7
Mean	2.86	2.99	6				2.76	2.96	6
SD	0.80	0.76	9				0.71	0.91	13
Geometric Mean				20.1	18.5	0.9				10.8	33.9	3.1†
95% CI				11.7,34.6	9.8,35.1	0.5,1.7				5.9,19.7	15.0,76.8	1.6,6.2

^*Fold change = PC₂₀ end/PC₂₀ beginning of period. The log of these values was used in the statistical analysis.

^†Significantly greater than placebo (p = 0.022).

^††Received prednisone during placebo. Subject #10 required two courses.